Drug Sponsors

Spectrum extends tender offer for shares of Allos Therapeutics

Tuesday, July 10, 2012 11:31 AM

Spectrum Pharmaceuticals, a biotech with a primary focus in oncology and hematology, has extended the offer period for its tender offer to purchase all of the outstanding shares of common stock of Allos Therapeutics, a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, for $1.82 per share in cash.

More... »

Albemarle expands South Haven API production site

Tuesday, July 10, 2012 11:19 AM

Albemarle, a global developer, manufacturer and marketer of highly engineered specialty chemicals, has begun upgraded and expanded its FDA-registered multi-product cGMP active pharmaceutical ingredient (API) manufacturing facility in South Haven, Mich.

More... »

Genkyotex raises $26M in Series C round extension

Monday, July 9, 2012 04:01 PM

Genkyotex, a Swiss developer of NOX inhibitors to treat oxygen-radical mediated diseases, has closed a $26 million extension to its Series C financing. Investors in the Series C round, including Eclosion, Edmond de Rothschild Investment Partners, Vesalius Biocapital Partners, MP Healthcare Venture, all participated in the financing extension.

More... »

Cardiome reduces work force by 85%

Monday, July 9, 2012 03:03 PM

Vancouver-based Cardiome Pharma, a research-based biopharmaceutical company, is undertaking a significant work force reduction in response to the recently announced termination of Merck's development efforts relating to the vernakalant oral program.

More... »

Savient appoints new CEO, cuts work force by 35%

Monday, July 9, 2012 02:37 PM

Savient Pharmaceuticals, a specialty biopharmaceutical company based in East Brunswick, N.J., has appointed Louis Ferrari, current executive vice president and president North American commercial operations, to the role of president and CEO.

More... »

R-Pharm licenses Merck hepatitis C drug

Friday, July 6, 2012 03:59 PM

The Russian pharmaceutical company R-Pharm—headed by the Ministry of Industry and Trade of the Russian Federation—entered into a licensing agreement with MSD (Merck) for rights to a novel investigational, hepatitis C once-daily protease inhibitor, narlaprevir. 

More... »

CRT and ADC Therapeutics partner on antibody drug conjugates

Friday, July 6, 2012 03:02 PM

Cancer Research Technology (CRT), the commercial arm of Cancer Research U.K., and Switzerland-based ADC Therapeutics have signed agreements to develop cancer treatments called antibody drug conjugates (ADCs) using CRT antibodies and peptides and ADCT's “warhead” and linker chemistries.

More... »

Pfizer grants ChemRar Group exclusive license to DPP-IVi T2D candidate

Friday, July 6, 2012 02:47 PM

Pfizer has granted  SatRx , a company belonging to Russian pharmaceutical investment and R&D group  ChemRar Hi-Tech Centre , exclusive development and marketing rights to for its DPP(1)-IVi compound, PF-00734200.

More... »

Sucampo Pharmaceuticals announces arbitration decision

Friday, July 6, 2012 02:32 PM

Sucampo Pharmaceuticals of Bethesda, Md.,has received a final binding decision on its claims in the dispute with its partner, Takeda Pharmaceutical: the International Court of Arbitration, International Chamber of Commerce (ICC) did not agree with Sucampo's claims and did not award any attorneys' fees or costs.

More... »

Amgen completes acquisition of KAI Pharmaceuticals

Friday, July 6, 2012 02:13 PM

Thousand Oaks, Calif.-based Amgen has completed the acquisition of KAI Pharmaceuticals, a privately held company based in South San Francisco.

More... »